Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 118

1 1. D'Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017; 23:1417–1421.

2 2. Majhail NS, Tao L, Bredeson C, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013; 19:1498–1501.

3 3. Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012; 30:71–77.

4 4. Vanderwalde AM, Sun CL, Laddaran L, et al. Conditional survival and cause‐specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. Leukemia. 2013; 27:1139–1145.

5 5. Afessa B, Abdulai RM, Kremers WK, et al. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest. 2012; 141:442–450.

6 6. Myers RM, Hill BT, Shaw BE, et al. Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma. Cancer. 2018; 124:816–825.

7 7. Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017; 102:614–625.

8 8. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic‐cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005; 105:4215–4222.

9 9. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614–7620.

10 10. Ulrickson M, Aldridge J, Kim HT, et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non‐Hodgkin lymphoma: a single‐institution experience. Biol Blood Marrow Transplant. 2009; 15:1447–1454.

11 11. O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990; 323:378–382.

12 12. Taylor PM, O'Driscoll BR, Gattamaneni HR, Woodcock AA. Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features. Clinical Radiol. 1991; 44:299–301.

13 13. Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980; 303:183–188.

14 14. Sano H, Kobayashi R, Iguchi A, et al. Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 2014; 49:38–41.

15 15. Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015; 21:1046–1053.

16 16. Rubio C, Hill ME, Milan S, et al. Idiopathic pneumonia syndrome after high‐dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer. 1997; 75:1044–1048.

17 17. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18:348–371.

18 18. Bhatia S, Armenian SH, Landier W. How I monitor long‐term and late effects after blood or marrow transplantation. Blood. 2017; 130:1302–1314.

19 19. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127:2824–2832.

20 20. Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011; 118:6023–6029.

21 21. Bleeker JS, Gertz MA, Pellikka PA, et al. Evaluation of pretransplant factors predicting cardiac dysfunction following high‐dose melphalan conditioning and autologous peripheral blood stem cell transplantation. Eur J Haematol. 2012; 89:228–235.

22 22. Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:1138–1144.

23 23. Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 2014; 32:191–198.

24 24. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007; 109:1765–1772.

25 25. Carey RM, Whelton PK. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018; 168:351–358.

26 26. Vaduganathan M, Hirji SA, Qamar A, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC: CardioOncology. 2019; 1:54–65.

27 27. Clasen SC, Scherrer‐Crosbie M. Applications of left ventricular strain measurements to patients undergoing chemotherapy. Curr Opin Cardiol 2018; 33:493–497.

28 28. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129:S1–45.

29 29. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377:111–121.

30 30. Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high‐dose chemotherapy and autograft, with or without rituximab: a 20‐year retrospective follow‐up study in patients with lymphoma. J Clin Oncol 2011; 29:814–824.

31 31. Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem‐cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006; 24:3604–3610.

32 32. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy‐related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000; 95:1588–1593.

33 33. Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem‐cell transplantation for lymphoma. J Clin Oncol. 2017; 35:1598–1605.

34 34. Bilmon IA, Ashton LJ, Le Marsney RE, et al. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population‐based cohort study. Bone Marrow Transplant. 2014; 49:691–698.

35 35. Sanchez‐Ortega I, Canals C, Peralta T, et al. Thyroid dysfunction in adult patients late after autologous and allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2012; 47:296–298.

36 36. Tauchmanova L, Selleri C, De Rosa G, et al. Endocrine disorders during the first year after autologous stem‐cell transplant. Am J Med 2005; 118:664–670.

37 37. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series. 1994; 843:1–129.

38 38. Buckley L, Humphrey MB. Glucocorticoid‐induced osteoporosis. N Engl J Med. 2018; 379:2547–2556.

39 39. Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation. Cancer. 2009; 115:4127–4135.

40 40. Yao S, Smiley SL, West K, et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:11301137.

41 41. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019; 393:364–376.

42 42. Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002; 118:58–66.

43 43. Schimmer AD, Ali V, Stewart AK, et al. Male sexual function after autologous blood or marrow transplantation. Biol Blood Marrow Transplant. 2001; 7:279–283.

44 44. Loren AW, Chow E, Jacobsohn DA, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011; 17:157–166.

45 45. Schimmer AD, Quatermain M, Imrie K, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 1998; 16:2359–2363.

46 46. Teinturier C, Hartmann O, Valteau‐Couanet D, et al. Ovarian function after autologous bone marrow transplantation in childhood: high‐dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998; 22:989–994.

47 47. Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001; 358:271–276.

48 48. Hingorani S. Renal complications of hematopoietic‐cell transplantation. N Engl J Med. 2016; 374:2256–2267.

49 49. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long‐term survivors of hematopoietic cell transplantation. Cancer. 2008; 113:1580–1587.

50 50. Hoffmeister PA, Hingorani SR, Storer BE, et al. Hypertension in long‐term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:515–524.

51 51. Cohen EP, Irving AA, Drobyski WR, et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2008; 70:1546–1551.

52 52. Jantunen E, Itala M, Siitonen T, et al. Late non‐relapse mortality among adult autologous stem cell transplant recipients: a nation‐wide analysis of 1,482 patients transplanted in 1990‐2003. Eur J Haematol. 2006; 77:114–119.

53 53. Ruiz‐Soto R, Sergent G, Gisselbrecht C, et al. Estimating late adverse events using competing risks after autologous stem‐cell transplantation in aggressive non‐Hodgkin lymphoma patients. Cancer. 2005; 104:2735–2742.

54 54. Lavoie JC, Connors JM, Phillips GL, et al. High‐dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long‐term outcome in the first 100 patients treated in Vancouver. Blood. 2005; 106:1473–1478.

55 55. Ahles TA, Tope DM, Furstenberg C, et al. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol. 1996; 14:1457–1462.

56 56. Chakraborty R, Hamilton BK, Hashmi SK, et al. Health‐related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2018; 24:1546–1553.

57 57. Andrykowski MA, Bishop MM, Hahn EA, et al. Long‐term health‐related quality of life, growth, and spiritual well‐being after hematopoietic stem‐cell transplantation. J Clin Oncol. 2005; 23:599–608.

58 58. Frodin U, Borjeson S, Lyth J, Lotfi K. A prospective evaluation of patients' health‐related quality of life during auto‐SCT: a 3‐year follow‐up. Bone Marrow Transplant. 2011; 46:1345–1352.

59 59. Mosher CE, DuHamel KN, Rini C, et al. Quality of life concerns and depression among hematopoietic stem cell transplant survivors. Support Care Cancer. 2011; 19:1357–1365.

60 60. Ahmedzai SH, Snowden JA, Ashcroft AJ, et al. Patient‐reported outcome results from the Open‐Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem‐Cell Transplantation in Relapsed Multiple Myeloma. J Clin Oncol. 2019; 37:1617–1628.

61 61. Syrjala KL, Langer SL, Abrams JR, et al. Recovery and long‐term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA. 2004; 291:2335–2343.

62 62. Costa DSJ, Fardell JE. Why are objective and perceived cognitive function weakly correlated in patients with cancer? J Clin Oncol. 2019; 37:1154–1158.

63 63. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high‐risk breast cancer: high‐dose versus standard‐dose chemotherapy. J Natl Cancer Inst. 1998; 90:210–218.

64 64. Jacobs SR, Small BJ, Booth‐Jones M, et al. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer. 2007; 110:1560–1567.

65 65. Karschnia P, Parsons MW, Dietrich J. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 2019; 20:e92–e102.

66 66. Moskowitz CH, Walewski J, Nademanee A, et al. Five‐year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018; 132:2639–2642.

67 67. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem‐cell transplantation in mantle‐cell lymphoma. N Engl J Med. 2017; 377:1250–1260.

68 68. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013; 13:106–111.

69 69. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR Summary Slides 2018. Available from: https://www.cibmtr.org ().

70 70. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer. 1987; 55:523–529.

71 71. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol. 2000; 65:123–127.

72 72. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958‐1996: a search for common mechanisms. Br J Cancer. 2001; 85:997–1005.

73 73. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem‐cell transplantation in newly diagnosed multiple myeloma: a meta‐analysis. J Clin Oncol. 2017; 35:3279–3289.

74 74. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta‐analysis of individual patient data. Lancet Oncol. 2014; 15:333–342.

75 75. Mahindra A, Raval G, Mehta P, et al. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015; 21:738–745.

76 76. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996; 95:349–353.

77 77. Mouhieddine TH, Park J, Redd RA, et al. The role of clonal hematopoiesis of indeterminate potential (CHIP) in multiple myeloma: immunomodulator maintenance post autologous stem cell transplant (ASCT) predicts better outcome. Blood. 2018; 132:749.

78 78. Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib‐associated cardiovascular adverse events: a systematic review and meta‐analysis. JAMA Oncol. 2018; 4:e174519.

79 79. Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015; 21:2039–2051.

80 80. Angel‐Korman A, Stern L, Sarosiek S, et al. Long‐term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019; 95:405–411.

81 81. Khera N, Chow EJ, Leisenring WM, et al. Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2011; 17:995–1003.